Psoriatic Arthritis Clinical Trial Pipeline Expands as 20+ Pharma Companies Progress 25+ Novel Therapies Toward Market Entry, Finds DelveInsight | Bristol Myers Squibb, Hansoh BioMedical R&D Company and others

DelveInsight's "Psoriatic Arthritis - Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies developing 25+ pipeline drugs in the Psoriatic Arthritis pipeline landscape. It covers the Psoriatic Arthritis pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.​

Explore the latest breakthroughs in the Psoriatic Arthritis treatment landscape. Learn more about the evolving Psoriatic Arthritis pipeline today @ https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Psoriatic Arthritis Pipeline Report​

• On 9th March 2026, the FDA approved pharma major Bristol Myers Squibb's (NYSE; BMY) Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA). Sotyktu, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first TYK2 inhibitor to be approved for PsA.
• In September 2025, the FDA approved guselkumab (Tremfya) for pediatric PsA - first IL-23 inhibitor approved for children aged ≥6 years (≥40 kg) with active psoriatic arthritis, supported by the Phase 3 PROTOSTAR trial.
• In July 2025, Janssen initiated a Phase 3 study evaluating icotrokinra vs. placebo in active PsA, assessing reduction in signs and symptoms.
• DelveInsight's Psoriatic Arthritis Pipeline Insight report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Psoriatic Arthritis treatment.​
• The leading Psoriatic Arthritis companies include Bristol Myers Squibb, Hansoh BioMedical R&D Company, selection and others.​
• Promising Psoriatic Arthritis therapies include Sotyktu (deucravacitinib), HS-10374, si-544 and others.​

Download for updates and the latest revolution in Psoriatic Arthritis treatment @ https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Psoriatic Arthritis Pipeline Report Provides​

• Detailed insights about companies developing therapies for Psoriatic Arthritis, with aggregate therapies developed by each company.​
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Psoriatic Arthritis treatment.​
• Psoriatic Arthritis companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.​
• Psoriatic Arthritis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.​
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Psoriatic Arthritis market.​

Learn more about Psoriatic Arthritis Drugs opportunities in our comprehensive Psoriatic Arthritis pipeline report @
https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
​
Psoriatic Arthritis Companies​

There are 20+ key companies, such as Bristol Myers Squibb, Hansoh BioMedical R&D Company, selection and others, developing therapies for Psoriatic Arthritis, with Bristol Myers Squibb having its Psoriatic Arthritis drug candidate in the most advanced Phase III stage.​

DelveInsight's Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:​

• Oral​
• Intravenous​
• Subcutaneous​
• Intramuscular​
• Topical​

Psoriatic Arthritis products have been categorized under various Molecule types such as:​

• Recombinant fusion proteins​
• Small molecule​
• Monoclonal antibody​
• Peptide​
• Polymer​
• Gene therapy​

Discover the latest advancements in Psoriatic Arthritis treatment by visiting our website. Stay informed @
https://www.delveinsight.com/report-store/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
​
Scope of the Psoriatic Arthritis Pipeline Report​

• Coverage: Global​
• Psoriatic Arthritis companies: Bristol Myers Squibb, Hansoh BioMedical R&D Company, selection and others​
• Psoriatic Arthritis Therapies: Sotyktu (deucravacitinib), HS-10374, si-544 and others.​
• Psoriatic Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination​
• Psoriatic Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III​

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.​

This release was published on openPR.